SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001437749-24-012044 from Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)

Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: April 15, 2024 · CIK: 0001029125 · Accession: 0001437749-24-012044

AI Filing Summary & Sentiment

File numbers found in text: 333-278403

Date
April 15, 2024
Author
Not clearly detected
Form
CORRESP
Company
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)

Letter

pbla20240415_corresp.htm

April 15, 2024

VIA EDGAR TRANSMISSION

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

Attn:

Jessica Dickerson

Re:

Panbela Therapeutics, Inc.

Registration Statement on Form S-1 (Registration No. 333-278403)

Request for Acceleration of Effective Date

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-278403) (the “Registration Statement”) to become effective on April 15, 2024, at 5:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.

[Signature Page Follows]

Very truly yours,
PANBELA THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

	pbla20240415_corresp.htm

April 15, 2024

VIA EDGAR TRANSMISSION

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

			Attn:

			Jessica Dickerson

			Re:

			Panbela Therapeutics, Inc.

			Registration Statement on Form S-1 (Registration No. 333-278403)

			Request for Acceleration of Effective Date

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-278403) (the “Registration Statement”) to become effective on April 15, 2024, at 5:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.

[Signature Page Follows]

			Very truly yours,

			PANBELA THERAPEUTICS, INC.

			By:

			/s/ Susan Horvath

			Name:

			Susan Horvath

			Title:

			Chief Financial Officer